OTHER INFORMATION.
−Removed: Not applicable
+Added: In order to comply with Section 122 of the NYSE American Company Guide, on August 9, 2022 the Company and the holder of the Company’s Series C preferred stock and Series D preferred stock amended the Securities Purchase Agreement entered into between them on July 28, 2022 to provide that the holder may only submit 1,549,295 of the votes relating to the Series C Preferred Stock that it would otherwise be entitled to vote.
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
4 unchanged sentences
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
+Added: August 11, 2022
EXHIBIT INDEX
23 unchanged sentences
Certificate of Amendment to the Certificate of Designation for the Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K/A filed on February 1, 2021 File No.
−Removed: Employment Agreement effective January 3, 2022 between Synthetic Biologics, Inc.
−Removed: and Steve Shallcross (Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed on January 4, 2022 File No.
−Removed: Employment Agreement effective March 22, 2022 between Synthetic Biologics, Inc.
−Removed: and Frank Tufaro (Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed on March 23, 2022 File No.
+Added: Certificate of Change Pursuant to NRS 78.
+Added: 209 (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed July 25, 2022, File No.
+Added: Form of Certificate of Designation of Series C Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed July 29, 2022, File No.
+Added: Form of Certificate of Designation of Series D Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed July 29, 2022, File No.
+Added: Securities Purchase Agreement between Synthetic Biologics Inc.
+Added: and MSD Credit Opportunity Master Fund, L.P., dated as of July 28, 2022(Incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed July 29, 2022, File No.
+Added: Amendment No.
+Added: 1 dated as of August 9, 2022 to Securities Purchase Agreement between Synthetic Biologics Inc.
+Added: and MSD Credit Opportunity Master Fund, L.P., dated as of July 28, 2022
Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)*
11 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.